Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Feb 13, 2008	EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference LYON, France, Feb. 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief Executive	View HTML EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference 9 KB
Toggle Summary Feb 07, 2008	EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues Record Fourth Quarter Revenue Financial Highlights: Full year revenues of Euro 22.2 million, up 10% year-over-year Record fourth quarter revenue of Euro 7.0 million, up 43% year-over-year Robust 42% full year revenue attributed to Ablatherm-HIFU Ablatherm-HIFU RPP treatments increased 36% year-over-year; 40% from fourth quarter 2006 Approximately 3,400 Ablatherm-HIFU treatments worldwide for year, yielding 15,000 cumulative treatments at 176 clinical sites Successful launch of integrated Sonolith I-Sys for the disintegration of urinary stones	View HTML EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues 12 KB
Toggle Summary Feb 07, 2008	Dr. Andrew Weil on Ablatherm-HIFU Dr. Andrew Weil on Ablatherm-HIFU We are proud to announce that Dr. Andrew Weil, a well-known physician and author, recently spoke of the benefits associated with Ablatherm-HIFU minimally invasive, robotized technology. Please click on the below link to view Dr.	View HTML Dr. Andrew Weil on Ablatherm-HIFU 8 KB
Toggle Summary Feb 07, 2008	Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007 45% Year-Over-Year Treatment Growth Continues to Drive Adoption At Munich Center	View HTML Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007 12.3 KB
Toggle Summary Feb 01, 2008	EDAP Launches First Sonolith I-Sys Unit in Europe 60 Patients Successfully Treated With Sonolith I-Sys in Poland	View HTML EDAP Launches First Sonolith I-Sys Unit in Europe 11.9 KB
Toggle Summary Jan 29, 2008	EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer IRBs Approve Five Additional Sites 12 Active Sites Now Screening and Enrolling Patients	View HTML EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer 13.5 KB
Toggle Summary Jan 24, 2008	EDAP Retains The Ruth Group as Investor Relations Counsel EDAP Retains The Ruth Group as Investor Relations Counsel LYON, France, Jan. 24, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announced today that it has retained The Ruth Group as its investor relations	View HTML EDAP Retains The Ruth Group as Investor Relations Counsel 10.2 KB
Toggle Summary Dec 14, 2007	EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17 Celebrating Launch of U.S. Study and 10 Years as NASDAQ Company CEO, CFO and Medical Director Available for Media Interviews	View HTML EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17 10.9 KB
Toggle Summary Dec 13, 2007	EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer LYON, France, Dec. 13, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the release of the first multi-center	View HTML
Toggle Summary Dec 05, 2007	EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical Center is First in Tennessee to Evaluate New HIFU System for Prostate Cancer	View HTML EDAP Ablatherm Clinical Study Begins At Vanderbilt Medical 12.1 KB